Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Featured Content
Intuitive Surgical's Selloff Sets Up a 30% Rebound OpportunityWritten by Thomas Hughes. Date Posted: 4/23/2026. 
Key Points
- Instuitive Surgical hit bottom in early 2026 and is set up to rebound robustly.
- Accelerting device placement, procedure volume, and consumable supplies underpin the growth outlook.
- Competition exists but trails significantly, leaving this company with a wide moat.
- Special Report: Elon’s “Hidden” Company
Intuitive Surgical’s (NASDAQ: ISRG) primary headwinds are its high valuation and slowing growth. That combination has weighed on price action since early 2025 and is unlikely to disappear soon. However, the current valuation already prices in solid growth expectations, which may understate the company’s upside potential. Intuitive Surgical’s advantage lies in its dominance of robotic surgical procedures. The company is a first mover, with an installed base of more than 12,000 devices and growing. In that context, a 45X valuation relative to current-year earnings looks less daunting, especially given the potential for a 50% or greater stock price increase over the next few years.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
And that is assuming the long-term forecasts are accurate. Historically, Intuitive Surgical has consistently outperformed expectations, with device deployments and procedure volumes continuing to expand. More likely, ISRG will continue to outperform and trigger a bullish revision cycle over the long term. Market Overreaction Sets Up ISRG OpportunityAnalysts played a role in ISRG’s stock price decline in 2026. The trend before the fiscal Q1 2026 release was downward price target revisions, but the market overreacted, creating a deep-value opportunity. The revision trend supports the consensus price target, which implies more than 30% upside from key support levels, and there is high conviction behind that forecast. MarketBeat tracks 25 analysts, who rate the stock a consensus Moderate Buy, with a 68% buy-side bias reflected in institutional activity. The institutional activity is notable. Institutions own more than 80% of the stock and have been accumulating throughout the corrective period. Their activity ramped into Q1 2026 and remained strong in the early weeks of Q2. The trailing 12-month balance is nearly 2-to-1 in favor of buyers, with Q1 and Q2 activity reflecting accelerating demand. The takeaway: ISRG has a solid floor in the $445 to $450 region and is positioned for a robust rebound in Q2 and the latter part of 2026. Stock price action mirrors the institutional activity, with declines halting near $445 and rebounds following. The mid-Q2 setup favors a rebound, with the market showing support at the critical level and advancing after the Q1 release. Indicators such as MACD and stochastic are aligned, suggesting a trend-following move that could carry the market back to record levels. Technical hurdles include the long-term 150-day exponential moving average near $500 and resistance at prior peaks near $560 and $600. Buybacks Add Leverage: Underpin Stock Price OutlookBuybacks are one reason this stock can reach new highs. In addition to operational outperformance and improving forward estimates, buybacks have enhanced shareholder leverage. The Q1 release showed more than $1.1 billion in quarterly repurchases, enough to reduce the share count by roughly 0.15% sequentially and about 1.3% year over year, with capacity to continue buying at a robust pace. Intuitive Surgical’s balance sheet reflects the effects of buybacks and acquisitions but is supported by strong cash flow and increased shareholder leverage. Key points include reduced cash offset by lower liabilities and relatively steady equity. In this posture, ISRG can continue repurchases while maintaining balance sheet health, including a zero-debt position. At present, Intuitive Surgical is net cash relative to total liabilities, with cash more than 3.15X liabilities—among the strongest balance sheets on Wall Street. Intuitive Surgical’s Q1 Release Triggers Market ReboundIntuitive Surgical had a robust Q1, reinforcing its trends and suggesting forward estimates may be conservative. Net revenue of $2.77 billion rose 23.1% year over year, outpacing consensus by more than 550 basis points. Growth was driven by device placements (up 17%), procedure volume (up 17%), and instrument sales (up 23%). The installed base grew 12%, signaling continued gains in coming quarters, and margins improved. Adjusted net income grew 36%, outpacing the top line by more than 1,300 basis points, and is expected to remain strong in upcoming quarters. Guidance calls for full-year da Vinci device growth of approximately 14.5%, with procedures and instrument sales following suit. The biggest risk, outside of valuation, is competition, though rivals currently trail. The closest challenger is Medtronic’s (NYSE: MDT) Hugo system, which has seen success overseas but remains in early rollout stages. Catalysts for ISRG include the early success of da Vinci 5, AI-enabled opportunities, and international expansion. Japan, specifically, recently approved seven new robotic procedures and is expected to be a significant growth driver. |
0 Response to "We're excited to have you on board"
Post a Comment